SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy is trending as investors monitor regulatory developments, specifically the shift toward Part 53 licensing, which could accelerate commercial review processes for their molten salt reactor technology. The community is actively debating the company's long-term potential as a critical infrastructure play for AI data centers while weighing the risks of early-stage reactor development against its current cash position.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is seeing intense community engagement as investors weigh long-term nuclear demand against the stock's recent valuation premium and quarterly results. While sentiment remains divided over short-term price action, there is strong, consistent support for the sector's role in powering AI infrastructure and national energy security.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus Energy Corp is gaining significant attention as investors react to a major government funding award aimed at accelerating domestic uranium enrichment capabilities. The community is actively discussing the stock's pivotal role in the nuclear fuel supply chain, with many highlighting its position as a primary beneficiary of the growing demand for HALEU and the broader nuclear renaissance.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano is trending as the community highlights the project's integration of real-world revenue from its food business to drive token buybacks and passive income mechanics. Investors are actively discussing the project's long-term potential as an RWA memecoin on the Cardano blockchain, frequently referencing its community-led initiatives and upcoming events.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a report that GameStop is building a stake in the company ahead of a potential takeover bid. While the community is actively debating the feasibility and financial logistics of such an acquisition, sentiment remains divided between those expecting a strategic expansion and others skeptical of the deal's structure and viability.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWX Technologies is capturing investor interest as a vital player in the nuclear energy sector, fueled by its role in supplying reactor components for both government defense projects and emerging small modular reactor (SMR) initiatives. The community is actively discussing the stock's long-term potential as a 'picks and shovels' play on nuclear energy infrastructure, particularly as demand for power in AI data centers continues to surge.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is facing heightened community attention as investors debate the impact of pending NRC construction permit applications against broader sector-wide volatility. Market participants remain sharply divided, with some highlighting the company's potential for a short squeeze and technological growth while others voice concerns regarding pre-revenue status and recent insider selling patterns.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing active community debate as investors weigh potential market recovery against long-term skepticism, while high-volume traders continue to monitor supply levels and ecosystem developments. Sentiment remains polarized between those holding for a long-term supply shock and others who view the asset as a speculative trap in the current cycle.

SkyAI is an all-in-one AI ecosystem powered by MCP, designed to seamlessly integrate intelligent solutions across industries.

SkyAI

SkyAI is seeing intense momentum driven by speculative interest in the AI-crypto sector, with traders debating whether the asset represents a sustained breakout or a pump-and-dump scheme. Community discussion is polarized between optimistic holders highlighting rapid volume gains and cautious investors warning of potential volatility after a sharp rise in market visibility.

Green Satoshi Token

The Green Satoshi Token (GSTSOL) community is actively discussing potential breakout catalysts like anticipated altseason trends, increased volume, and whale accumulation, despite skepticism regarding supply dilution and past price performance. Bulls remain highly focused on technical indicators and social media momentum as they monitor the token for significant volatility and a sustained upward reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Psyence Biomedical Stock Falling Wednesday?

Psyence Biomedical faces a double-digit decline Tuesday as traders lock in gains following a massive 250% speculative rally last Thursday.read more...

<ul class="summary-bullets"><li>Momentum across psychedelic stocks gained after Trump signed an exec order directing the FDA to accelerate review of psychedelic therapies and committed $50 million towards research.</li><li>The company said it holds standardized, stabilized GMP-compliant ibogaine doses in inventory in a market where access to clinical-grade material remains limited.</li><li>Through its investment in PsyLabs, Psyence has built a vertically integrated platform spanning sourcing in Africa through extraction, purification and pharma production.</li></ul>Shares of Psyence Biomedical (PBM) surged into the spotlight again on Monday after the company underscored its pharma-grade ibogaine inventory advantage just as a new White House order boosted momentum behind psychedelic medicine research.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has logged a three-day winning streak, gaining 182% over the same period.&nbsp;<h2 class="st-heading-2">PBM Targets Global Ibogaine Supply Gap</h2>Psyence Biomedical said on Monday that it currently holds standardized, stabilized and Good Manufacturing Practice (GMP)-compliant ibogaine doses in inventory in a market where access to pharma-grade material remains limited and fragmented.Through its investment in PsyLabs, the company has built an integrated platform spanning sourcing at origin in Africa through extraction, purification and pharmaceutical production.&nbsp;“With limited GMP-grade ibogaine available globally, infrastructure and supply capabilities are the differentiator,” CEO Jody Aufrichtig said. “Our Company is positioned not only to support our own programs, but to enable the broader ecosystem as interest in ibogaine continues to grow.”The company added that its vertically integrated platform can reduce delays tied in supply constraints that have historically slowed progress in ibogaine-based clinical research.<h2 class="st-heading-2">PBM Rides FDA Psychedelic Review Momentum</h2>The supply update comes shortly after U.S. President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite review of psychedelic medicines, including ibogaine, while committing $50 million in funding toward related clinical-research programs.At the Oval Office signing ceremony, Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence, particularly for veterans with serious mental-health conditions.&nbsp;Ibogaine, a compound derived from a Central and West African shrub, remains classified as a Schedule I substance in the U.S. but has attracted growing attention for its potential role in treating post-traumatic stress disorder.The policy move triggered a broad rally across psychedelic-therapy developers. Shares of Enveric Biosciences (ENVB) surged 101%, Compass Pathways (CMPS) jumped 42%, Atai Life Sciences (ATAI) gained 22%, and Definium Therapeutics (DFTX) rose 2% on Monday.<h2 class="st-heading-2">PBM Builds Ibogaine Supply From Africa&nbsp;</h2>Operating near ibogaine’s natural source in Central and West Africa, PsyLabs has secured direct access to raw material with in-region processing to support traceable, reliable, and ethically sourced supply.&nbsp;Earlier this year, Psyence said it produced high-purity ibogaine hydrochloride from ethically sourced iboga bark and exported a GMP-compliant psilocybin product, NPX-5, to Australia for a Phase IIb trial in adjustment disorder among patients receiving palliative cancer care.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM was ‘extremely bullish’ amid an eye-watering 82,550% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_36a8236907.webp" alt="pbm ss.png" width="967" height="133"><figcaption>TSLA sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/LowDownDog12/message/650809854">said</a>, “Still holding my 5200 shares at 2.40. Bought believing this company could be the first to get ibogaine to market and still do.”<stembedurl>https://stocktwits.com/LowDownDog12/message/650809854</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/livetotradestox/message/650823742">noted</a> PBM's description of itself as the world’s only licensed pharma-grade ibogaine supplier at source level, and said: "Only sounds like a monopoly. At the very least a moat because of high barriers to entry for competitors."<stembedurl>https://stocktwits.com/livetotradestox/message/650823742</stembedurl>The stock has declined 48% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-founder-bull-case-anktiva-breast-cancer-signal/cZBIIqmRICd">IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal</a>

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock Trips Into Spotlight Again: Rare Ibogaine Supply Edge Gets Boost From Trump’s Psychedelic Push

PBM stock extended its rally to a three-day winning streak, gaining about 182% over the period as investors focused on supply benefits in the ibogaine ecosystem.

Equity

Top Small Cap Stocks To Keep An Eye On - April 20th

Spring Valley Acquisition, Enveric Biosciences, and Psyence Biomedical are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small cap stocks are shares of...

From Concrete to Consciousness: Wall Street Chases QXO $17B Megadeal and Psychedelic Moonshots

The week’s first power hour includes a powerful cross-sector narrative: hard assets meet high-concept science. On one side, a massive consolidation in construction materials signals long-term conviction in infrastructure and development. On the other, a cluster of small- and mid-cap biotech names, many tied to next-generation mental health treatments, are catching momentum simultaneously. $PBM, $QXO, $BLD, $XERI, $TOVX, $POET, $SLNH, $ATAI, $PBM, $CMPS

<ul class="summary-bullets"><li>Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares.</li><li>Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.</li><li>Further, data from Atai’s mid-stage trial of VLS-01 in treatment-resistant depression is expected in the second half of 2026.</li></ul> Shares of AtaiBeckley Inc. (ATAI) surged 28% on Monday and are on track for their best single-day gain if the rally holds, following analyst price target hikes and growing optimism across the psychedelic drug sector after President Trump signed an executive order to accelerate research in the field.Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, while also committing $50 million to federal research into the psychedelic compound called ibogaine.The move boosted shares of companies including Definium Therapeutics (DFTX), Compass Pathways (CMPS), Enveric BioSciences (ENVB), and Psyence Biomedical (PBM), among others.<h2 class="st-heading-2">Wall Street Boost</h2>Separately, Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. Atai is now preparing for BPL-003 to enter a late-stage trial this quarter. The investigational drug is a fast-acting psychedelic designed for treatment-resistant depression (TRD) and alcohol use disorder.The analyst now expects the company to price BPL-003 at a net annual price of $30,000 at launch, in line with Janssen Pharmaceuticals's Spravato nasal spray already approved for treatment-resistant depression. Further, data from Atai’s mid-stage trial of VLS-01 in TRD is expected in the second half of 2026, the analyst noted.Guggenheim, meanwhile, raised the firm's price target on AtaiBeckley to $16 from $11 and kept a ‘Buy’ rating on the shares on Friday. The firm said that it recently met with Atai management, which reinforced its "conviction" in the BPL-003 program heading into late-stage initiation this quarter, the analyst told investors.According to data from Koyfin, all 14 analysts covering ATAI rate it ‘Buy’ or higher. The 12-month average price target on the stock is $13.83, representing a potential upside of about 166% from current trading levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ATAI stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism about the stocks of psychedelic drug developers including ATAI to “trend up for a while.” “This will be a good ride,” they said.<stembedurl>https://www.stocktwits.com/twiggs462/message/650773904</stembedurl>Another user cheered Atai’s great assets and voiced hopes for further rallies in future.<stembedurl>https://www.stocktwits.com/brunoq14/message/650772195</stembedurl><a href="https://stocktwits.com/symbol/ATAI">ATAI stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/agio-stock-slumps-whats-the-novo-connection/cZBd0tMRIzi">AGIO Stock Slumps 25% – What’s The Novo Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers

Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, spurring a rally among psychedelic drug developer stocks. 

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.read more...

Rogan’s Runners Market Ignites

The market is feeling the effect of Joe Rogan getting in President Trump’s ear and psychedelic therapeutics gaining regulatory tailwinds. Meanwhile, adjacent sectors are quietly building foundational breakthroughs. Wearables are evolving into neural interfaces, biomaterials are transitioning from lab curiosity to production reality, and oncology platforms continue their grind through clinical validation. $KBLB, $WLDS, $ARTL, $ENVB, $TOVX, $PBM, $CMND, $CMPS, $HELP,

<ul class="summary-bullets"><li>U.S. stock futures pulled back early Monday, cooling off after last week’s record-setting gains.</li><li>Investors are monitoring a renewed flare-up in the Strait of Hormuz, after Iran signaled the critical shipping route would remain restricted amid an ongoing standoff with the U.S.</li><li>Psychedelic stocks catch a policy tailwind around expedited drug approvals for mental health treatment: PBM, DFTX, and CMPS are seeing retail attention.&nbsp;</li></ul>U.S. stock futures were under pressure early Monday, after reaching record highs last week amid&nbsp;easing geopolitical&nbsp;fears in the Middle East. However, tensions are on the rise again after President Donald Trump confirmed the seizure of an Iranian-flagged cargo ship in the Strait of Hormuz, prompting Iran to re-close the vital waterway.Trump threatened to "knock out every power plant" in Iran if a new deal is not reached during upcoming talks in Islamabad this week. Oil-linked stocks such as BATL and EONR are back on the radar following a spike in crude volatility.As of 4:00 a.m. ET on Monday, S&amp;P 500 and Nasdaq futures fell 0.6%, Dow futures slipped 0.7%, and Russell 2000 futures were down 1%.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, remained ‘extremely bullish.’Trending Stocks To WatchPsyence Biomedical (PBM):&nbsp;Retail is piling into this little-known psychedelic supplier following U.S. President Donald Trump’s executive order over the weekend to expedite the review of psychedelic medicines, including ibogaine and psilocybin for PTSD and addiction treatment. Also watch out for&nbsp;Definium Therapeutics (DFTX) and Compass Pathways (CMPS).&nbsp;Marvell (MRVL):&nbsp;Reports suggest that Google is in talks with the firm to design two new AI chips, including a next-generation TPU.&nbsp;AST SpaceMobile (ASTS):&nbsp;The stock fell 14% in early pre-market trading after the company confirmed that its BlueBird-7 satellite, launched on New Glenn 3, was placed in an orbit too low to sustain operations.&nbsp;Fermi LLC (FRMI):&nbsp;The stock cracked 16% in early pre-market trade on Monday following a massive leadership overhaul. Early this morning, Fermi announced a transition from its "start-up" roots to a "scaled enterprise.”Critical Metals Corp. (CRML):&nbsp;Remains on retail radar following the updates for its Tabrez project. Meanwhile, on Sunday, Chairman Tony Sage said in a social media post that, while the geopolitical situation has made shipping logistics "tricky," the company still targets Q2 2026 for operations at its Greenland pilot plant.Eli Lilly (LLY):&nbsp;Reports suggest that the company is in advanced talks to acquire Kelonia Therapeutics for over $2B, a deal that could be announced as early as today.Tesla, Inc (TSLA):&nbsp;The stock is on track for its first positive month this year, ahead of its earnings report this week. Meanwhile, Elon Musk downplayed competitive fears from China’s BYD, framing execution and not competition as the EV maker’s key challenge.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included AEVEX Corp (AVEX), Blackberry (BB), and Nvidia Corp (NVDA).&nbsp;Other Catalysts To WatchOn the economic front, no notable data release is expected.On earnings radar, watch out for quarterly reports from Cleveland-Cliffs Inc (CLF), Nano X Imaging Ltd (NNOX), and Dynex Capital Reit Inc (DX) before the bell. Also, Lion Group Holding Ltd (LGHL), AGNC Investment Corp (AGNC), Lottery.com Inc (SEGG), and Alaska Air Group Inc (ALK) report after market close on Monday.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall, Oil Risk Back In Focus After Trump’s Iran Escalation: Why PBM, FRMI, ASTS, BATL Are Keeping Traders Engaged Today

Data from Stocktwits shows that retail positioning has remained ‘bullish’ for SPY and QQQ amid geopolitical instability. 

<ul class="summary-bullets"><li>Trump directed the FDA to expedite reviews of psychedelic medicines, including ibogaine, and committed $50 million in funding for clinical research.</li><li>The company recently produced medical-grade ibogaine hydrochloride from an ethically sourced African supply.</li><li>Last month, Psyence exported GMP-compliant psilocybin to Australia for use in a Phase IIb clinical trial.</li></ul>Shares of Psyence Biomedical (PBM) surged over 111% to top premarket gains across U.S. stocks on Monday after U.S. President Donald Trump’s executive order accelerating psychedelic therapy research spotlighted the supply infrastructure behind post-traumatic stress disorder (PTSD) treatments such as ibogaine.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> surged 185% last week, marking its strongest weekly performance in more than two years.<h2 class="st-heading-2">Trump Commits $50M To Psychedelic Research</h2>Over the weekend, Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite the review of psychedelic medicines including ibogaine, while committing $50 million in federal funding toward related clinical research programs.Speaking at the Oval Office signing ceremony, Trump said emerging psychedelic treatments could have a “tremendous impact” if supported by clinical evidence and highlighted their potential role in addressing serious mental-health conditions affecting veterans.&nbsp;Ibogaine, derived from a shrub native to Central and West Africa, remains classified as a Schedule I substance in the U.S. despite growing interest from veterans’ advocacy groups studying its potential use in treating PTSD.<h2 class="st-heading-2">PBM Manufacturing Strategy In Spotlight</h2>A day before the executive order was signed, Psyence CEO Jody Aufrichtig said, “Ibogaine has emerged as a compound of increasing global interest, particularly for its potential to address complex and treatment-resistant conditions.” He added that expanding regulated clinical research would be essential to improving both patient safety and long-term access to ibogaine-based treatments.Through its investment in PsyLabs, the company has built a Good Manufacturing Practice (GMP)-compliant platform that produces pharma-grade psychedelic compounds, including ibogaine, for use in clinical research and drug-development programs.&nbsp;In January, the company said it produced high-purity ibogaine hydrochloride, a medical-grade form of the compound, from ethically sourced natural supply in Africa. The company had already secured access to high-potency iboga bark and established ibogaine operations in Africa through PsyLabs.Separately, last month, the company exported GMP-compliant psilocybin product NPX-5 to Australia for use in an ongoing Phase IIb clinical trial evaluating treatment for adjustment disorder in patients with cancer receiving palliative care.<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM has been ‘extremely bullish’&nbsp;for&nbsp;a week amid a whopping 15,100% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_5dfee3c956.webp" alt="pbm ss.png" width="959" height="142"><figcaption>PBM sentiment and message volume as of April 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/vvvvvvrebel89130/message/650702832">noted</a> that, “psyense is emphasizing their fully integrated supply chain with GMP Able to produce ibogaine at commercial scale.”<stembedurl>https://stocktwits.com/vvvvvvrebel89130/message/650702832</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/momoneyinfla/message/650678443">said</a>, “Not only is it signed they’re bringing the drug to market in weeks NOT years!!!&nbsp; This is gonna be up 500% on Monday”<stembedurl>https://stocktwits.com/momoneyinfla/message/650678443</stembedurl>PBM stock has declined 65% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dftx-vs-cmps-upside-trump-psychedelic-therapy-push/cZBdGeYRIy0">DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?</a>

Why Is PBM Stock More Than Doubling Premarket Today?

Through its investment in PsyLabs, the Psyence Biomedical company has built a GMP-compliant platform producing pharmaceutical-grade ibogaine.

Through its investment in PsyLabs, the company has built a GMP-compliant platform producing pharmaceutical-grade ibogaine.

Best Small Cap Stocks To Consider - April 17th

AltC Acquisition, Energy Focus, Critical Metals, Spring Valley Acquisition, Inflection Point Acquisition, Direxion Daily MU Bull 2X Shares, and Psyence Biomedical are the seven Small Cap stocks to...

This account has been verified as an official PBM representative.

Verified Account

Psyence BioMed

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

PBM
Psyence Biomedical Ltd.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PBM News

PBMPsyence Biomedical Ltd.